ClinicalTrials.gg
CompletedNCT03029143ENTERPRETUpdated Jul 28, 2023Results posted

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

A Phase 4 interventional study of Vedolizumab IV in Colitis, Ulcerative, sponsored by Takeda. Completed at 49 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
12th of 38
278 · median 110
Started
2017
with 7 others
Phase 4
15 of 38
2 open now
Registered
16th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 12th largest by enrollment, is one of 8 that started in 2017, is one of 15 in phase 4, and was the 16th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of vedolizumab intravenous (IV) dose optimization on mucosal healing compared with the standard vedolizumab IV dosing regimen over a 30 week treatment period in participants with moderately to severely active ulcerative colitis (UC) and high vedolizumab clearance, based on a Week 5 predefined serum vedolizumab concentration threshold less than (\<) 50 microgram per milliliter (microg/mL) and who are Week 6 non-responders based on partial Mayo score.

Read the detailed description

The drug being tested in this study is called Vedolizumab. Vedolizumab will be administered as an IV infusion. It is being tested in this study with new doses. This study will investigate the efficacy and safety of dose optimization of vedolizumab IV, compared with standard dosing of vedolizumab IV, over a 30-week treatment period.

The study will enroll approximately 250 moderately to severely active subjects with UC in order to randomize approximately 100 non-responder subjects with high vedolizumab drug clearance. Subjects will receive induction therapy of vedolizumab IV 300 mg on Day 1 and Week 2 (Lead-in Period). At Week 5, serum vedolizumab concentration will be measured. At Week 6, subjects will be assessed for clinical response based on partial Mayo score.

Results of both Week 5 vedolizumab concentration and Week 6 clinical response will determine the treatment pathway. Those who are non-responders based on partial Mayo score at Week 6 and who are assessed as having high vedolizumab clearance, based on a predefined Week 5 serum vedolizumab concentration threshold (\<50 microg/mL) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

  • Vedolizumab IV Standard Treatment
  • Vedolizumab IV Dose Optimized

All randomized subjects will receive vedolizumab IV either 300 mg or 600 mg every 4 or 8 weeks.

This multi-center trial will be conducted in United States of America and Canada. The overall time to participate in this study is 56 weeks. Subjects will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long term follow-up safety survey.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has a diagnosis of UC established at least 1 month prior to Screening by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Has moderately to severely active UC as determined by a complete Mayo score of 6 to 12 with an endoscopic subscore ≥2 within 28 days prior to enrollment.
  3. Has evidence of UC proximal to the rectum (≥15 cm of involved colon) prior to start of vedolizumab IV dosing.
  4. Has been determined to be suitable for vedolizumab IV for routine management of UC by their physician.
  5. Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during screening).
  6. Has demonstrated an inadequate response with, lost response to, or intolerance of at least 1 of the following agents: immunomodulators, , or tumor necrosis factor-alpha (TNF-α) antagonists. Subject who are naive to TNF-α antagonist therapy or who have previously failed TNF-α antagonist therapy (including primary and secondary non-responders or intolerant) may be included.

    Week 6 Randomized Treatment Period Inclusion Criteria

  7. Following Lead-in Period, the subject is assessed as having high vedolizumab drug clearance based on a predefined Week 5 serum vedolizumab concentration threshold (\<50 microg/mL).
  8. Following Lead-in Period, the subject is a non-responder based on partial Mayo score at Week 6.

Exclusion criteria

Exclusion Criteria:

  1. Has clinical evidence of abdominal abscess or toxic megacolon at the Screening Visit.
  2. Has had an extensive colonic resection, subtotal or total colectomy.
  3. Has had ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  4. Has a diagnosis of Crohn's colitis or indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.
  5. Has received any of the following for the treatment of underlying disease within 30 days of screening:

    1. Non-biologic therapies (eg. cyclosporine, tacrolimus, thalidomide)
    2. An approved non-biologic therapy in an protocol.
  6. Has received any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives prior to screening (whichever is longer).
  7. Has previously had prior exposure to approved or investigational anti-integrin antibodies (e.g. natalizumab, efalizumab, etrolizumab, AMG-181, anti-MAdCAM-1 antibodies or rituximab).
  8. Has previously received approved or investigational vedolizumab.
  9. The subject currently requires or is anticipated to require surgical intervention for UC during the study.
  10. Has history or evidence of adenomatous colonic polyps that have not been removed, or colonic mucosal dysplasia.
  11. Has any evidence of an active infection during Screening (eg, sepsis, cytomegalovirus, or listeriosis).
  12. Has a infection (eg, pneumonia, pyelonephritis) within 30 days prior to screening, or ongoing chronic infection.
  13. Has evidence of active C. difficile as evidenced by positive C. difficile toxin or is having treatment for C. difficile infection or other intestinal pathogens during Screening.
  14. Has a known history of infection with (HIV), (HBV), or chronic HBV (HBV immune subjects (ie, being hepatitis B surface antigen [HBsAg] negative and hepatitis B antibody positive) may, however, be included), or virus (HCV) infection. Subjects with documented successful treatment of HCV with sustained virological response (SVR) at 26 weeks can be enrolled.
  15. Has active or latent tuberculosis (TB), as evidenced by the following:

    a. A diagnostic TB test performed within 30 days of screening or during the Screening Period that is positive, defined as: i. Positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests, OR ii. A TB skin test reaction ≥ 5 mm OR, b. Chest X-ray within 3 months of screening that is suspicious for pulmonary TB, and a positive or 2 successive indeterminate QuantiFERON tests within 30 days prior to Screening or during the Screening Period.

  16. Has any identified congenital or acquired immunodeficiency (eg, common variable immunodeficiency, HIV infection, organ transplantation).
  17. Has any within 30 days prior to Screening or is planning to receive any live vaccination during participation in the study.
  18. Has used a topical (rectal) treatment with (5-ASA) or enemas/suppositories within 2 weeks prior to Screening.
  19. Has a history of or allergies to vedolizumab IV or its components.
  20. Has received total parenteral nutrition (TPN) or albumin in the last 30 days prior to screening.
  21. Has any unstable or uncontrolled cardiovascular disorder, heart failure moderate to severe (New York Class Association III or IV), any pulmonary, hepatic, renal, GI, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise subject safety.
  22. Has had a surgical procedure requiring general anesthesia within 30 days prior to screening or is planning to undergo major surgery during the study period.
  23. Has a history of , except for the following: adequately-treated non- basal cell skin cancer; squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to Screening; and history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to screening. Subjects with remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case by-case basis prior to Screening.
  24. Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, demyelinating, or neurodegenerative disease.
  25. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during Screening or prior to the administration of the first dose of study drug on Day 1.
  26. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
278 participants (actual)

Study arms

  • Experimental
    Lead-in Period: Vedolizumab 300 mg

    Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2. Participants who were non-responders based on partial Mayo score at Week 6 and who had high vedolizumab clearance (\>0.14 L/day) at Week 5 were eligible for Randomized Treatment Period (RTP). Participants who were responders (Lead-In Failures) entered the 18-week follow-up period and discontinued the study.

    Drug: Vedolizumab IV

  • Experimental
    Randomized Treatment Period (RTP): Standard Treatment Arm

    Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.

    Drug: Vedolizumab IV

  • Experimental
    RTP: Dose Optimized Arm

    Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.

    Drug: Vedolizumab IV

Interventions

  • Vedolizumab intravenous infusion.

    Also known as: Entyvio, MLN0002

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Mucosal Healing at Week 30

    Mucosal healing is defined as Mayo endoscopic subscore \<=1 point. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

    Time frame: Week 30

Secondary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 30

    Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

    Time frame: Week 30

  2. Percentage of Participants Achieving Clinical Response at Week 30

    Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point, at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

    Time frame: Week 30

  3. Percentage of Participants Achieving Clinical Response at Week 14

    Clinical response is defined as A reduction in partial Mayo score of ≥2 points and ≥25% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.

    Time frame: Week 14

  4. Percentage of Participants Achieving Corticosteroid-Free Remission

    Participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission. Mayo score was used in clinical trials to assess UC disease activity. Clinical Remission is defined as a complete Mayo score of \<=2 points and no individual subscore \>1 point at Week 30. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

    Time frame: Week 30

  5. Percentage of Participants Achieving Durable Clinical Response

    A clinical response (based on partial Mayo score), which is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at Weeks 14 and 30. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore. Percentage of participants with durable clinical response, clinical response achieved at both Weeks 14 and 30 are reported.

    Time frame: Weeks 14 and 30

07

Results

Posted Nov 11, 2021

Participant flow

Participants with ulcerative colitis (UC) took part in the study at 90 investigative sites in the United States and Canada from 29 March 2017 to 16 October 2020.

Lead-in Period (6 Weeks)
Participant flow — Lead-in Period (6 Weeks)
MilestoneLead-in Period: Vedolizumab 300 mgRandomized Treatment Period (RTP): Standard Treatment ArmRTP: Dose Optimized Arm
Started27800
Completed10900
Not completed16900
Withdrew: Pretreatment event/adverse event800
Withdrew: Significant protocol deviation1200
Withdrew: Lost to follow-up100
Withdrew: Voluntary withdrawal600
Withdrew: Randomized but not treated14200
Randomized Treatment Period (24 Weeks)
Participant flow — Randomized Treatment Period (24 Weeks)
MilestoneLead-in Period: Vedolizumab 300 mgRandomized Treatment Period (RTP): Standard Treatment ArmRTP: Dose Optimized Arm
Started05455
Not treated post randomization010
Safety population05355
Completed03131
Not completed02324
Withdrew: Pretreatment event/adverse event039
Withdrew: Significant protocol deviation013
Withdrew: Lost to follow-up013
Withdrew: Voluntary withdrawal0101
Withdrew: Lack of efficacy067
Withdrew: Reason not specified021

Outcome measures

PrimaryPercentage of Participants Achieving Mucosal Healing at Week 30

Mucosal healing is defined as Mayo endoscopic subscore \<=1 point. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Mucosal Healing at Week 30
percentage of participantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Mucosal Healing at Week 3018.9 (9.4 to 32.0)14.5 (6.5 to 26.7)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · Chi-squared · p = =0.401 · Odds ratio (or): 0.6 · 95% CI 0.2 to 1.8
SecondaryPercentage of Participants Achieving Clinical Remission at Week 30

Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore \>1 point at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 30
percentage of participantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Clinical Remission at Week 309.4 (3.1 to 20.7)9.1 (3.0 to 20.0)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · CMH Chi-square test · p = =0.943 · Adjusted risk difference: -0.4 · 95% CI -11.4 to 10.6
SecondaryPercentage of Participants Achieving Clinical Response at Week 30

Clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point, at Week 30. Mayo score was used in clinical trials to assess UC disease activity. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

Time frame:
Week 30
Reported as:
Number · percentage of particpants
Percentage of Participants Achieving Clinical Response at Week 30
percentage of particpantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Clinical Response at Week 3032.1 (19.9 to 46.3)30.9 (19.1 to 44.8)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · CMH Chi-square test · p = =0.893 · Adjusted risk difference: -1.2 · 95% CI -18.7 to 16.3
SecondaryPercentage of Participants Achieving Clinical Response at Week 14

Clinical response is defined as A reduction in partial Mayo score of ≥2 points and ≥25% from Baseline (Day 1) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore.

Time frame:
Week 14
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response at Week 14
percentage of participantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Clinical Response at Week 1434.0 (21.5 to 48.3)40.0 (27.0 to 54.1)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · CMH Chi-square test · p = =0.525 · Adjusted risk difference: 6.0 · 95% CI -12.4 to 24.3
SecondaryPercentage of Participants Achieving Corticosteroid-Free Remission

Participants using oral corticosteroids at Baseline who have discontinued corticosteroids and are in clinical remission. Mayo score was used in clinical trials to assess UC disease activity. Clinical Remission is defined as a complete Mayo score of \<=2 points and no individual subscore \>1 point at Week 30. It consisted of 4 disease activity variables (stool frequency, rectal bleeding, findings on sigmoidoscopy and physician's global assessment), each scored on a scale of 0 to 3, where 0 = normal condition and 3 = severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Corticosteroid-Free Remission
percentage of participantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Corticosteroid-Free Remission21.4 (4.7 to 50.8)14.3 (3.0 to 36.3)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · CMH Chi-square test · p = =0.623 · Adjusted risk difference: -6.6 · 95% CI -34.0 to 20.8
SecondaryPercentage of Participants Achieving Durable Clinical Response

A clinical response (based on partial Mayo score), which is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point at Weeks 14 and 30. Mayo score was used in clinical trials to assess UC disease activity. A composite index of 3 disease activity variables (stool frequency, rectal bleeding, and physician's global assessment), each scored on a scale from 0 to 3 with total partial Mayo score ranging from 0 to 9 (higher scores indicate greater disease activity). Partial Mayo score is calculated analogously to the complete Mayo score but excludes the sigmoidoscopy subscore. Percentage of participants with durable clinical response, clinical response achieved at both Weeks 14 and 30 are reported.

Time frame:
Weeks 14 and 30
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Durable Clinical Response
percentage of participantsRTP: Standard Treatment ArmRTP: Dose Optimized Arm
Percentage of Participants Achieving Durable Clinical Response22.6 (12.3 to 36.2)30.9 (19.1 to 44.8)
Statistical analysis
  • RTP: Standard Treatment Arm vs RTP: Dose Optimized Arm · CMH Chi-square test · p = =0.344 · Adjusted risk difference: 8.1 · 95% CI -8.5 to 24.7

Adverse events

Collected over From the first dose of study drug up to 18 weeks after the last dose (approximately 44 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lead-in Period1/278 (0.4%)12/278 (4.3%)10/278 (3.6%)
Lead-in Failure Follow-up Period0/170 (0%)1/170 (0.6%)4/170 (2.4%)
RTP: Standard Treatment Arm0/53 (0%)4/53 (7.5%)9/53 (17%)
RTP: VDZ Dose Optimization: Regimen A0/28 (0%)4/28 (14.3%)12/28 (42.9%)
RTP: VDZ Dose Optimization: Regimen B0/27 (0%)1/27 (3.7%)9/27 (33.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventLead-in PeriodLead-in Failure Follow-up PeriodRTP: Standard Treatment ArmRTP: VDZ Dose Optimization: Regimen ARTP: VDZ Dose Optimization: Regimen B
Colitis ulcerativeGastrointestinal disorders7/2781/1702/533/281/27
Abdominal pain lowerGastrointestinal disorders0/2780/1700/531/280/27
Benign familial haematuriaCongenital, familial and genetic disorders0/2780/1701/530/280/27
Clostridium difficile infectionInfections and infestations0/2780/1701/530/280/27
Viral upper respiratory tract infectionInfections and infestations0/2780/1701/530/280/27
Iron deficiency anaemiaBlood and lymphatic system disorders1/2780/1700/530/280/27
Abdominal painGastrointestinal disorders1/2780/1700/530/280/27
AppendicitisInfections and infestations1/2780/1700/530/280/27
Clostridium difficile colitisInfections and infestations1/2780/1700/530/280/27
Deep vein thrombosisVascular disorders1/2780/1700/530/280/27
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLead-in PeriodLead-in Failure Follow-up PeriodRTP: Standard Treatment ArmRTP: VDZ Dose Optimization: Regimen ARTP: VDZ Dose Optimization: Regimen B
Colitis ulcerativeGastrointestinal disorders2/2782/1704/530/283/27
HeadacheNervous system disorders8/2781/1701/533/282/27
DiarrhoeaGastrointestinal disorders0/2780/1700/533/282/27
C-reactive protein increasedInvestigations1/2781/1703/531/282/27
AnaemiaBlood and lymphatic system disorders0/2780/1701/530/282/27
FatigueGeneral disorders0/2780/1701/531/282/27
SinusitisInfections and infestations0/2780/1701/530/282/27
VomitingGastrointestinal disorders0/2780/1700/532/281/27
Abdominal pain upperGastrointestinal disorders0/2780/1700/532/280/27
CoughRespiratory, thoracic and mediastinal disorders0/2780/1701/532/280/27

Baseline characteristics

Safety analysis set Included all participants who were enrolled and received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Lead-in Period: Vedolizumab 300 mg
Mean40.9 ± 15.11
Sex: Female, Male
Sex: Female, Male(Participants)Lead-in Period: Vedolizumab 300 mg
Female122
Male156
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lead-in Period: Vedolizumab 300 mg
Hispanic or Latino34
Not Hispanic or Latino244
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lead-in Period: Vedolizumab 300 mg
American Indian or Alaska Native0
Asian18
Native Hawaiian or Other Pacific Islander2
Black or African American28
White228
More than one race2
Unknown or Not Reported0
Height
Height(cm)Lead-in Period: Vedolizumab 300 mg
Mean171.5 ± 9.39
Weight
Weight(kg)Lead-in Period: Vedolizumab 300 mg
Mean80.41 ± 20.112
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Lead-in Period: Vedolizumab 300 mg
Mean27.24 ± 5.942
Smoking Classification
Smoking Classification(Participants)Lead-in Period: Vedolizumab 300 mg
Participant has never smoked179
Participant is a current smoker12
Participant is an ex-smoker87
08

Study locations

49 sites
  • Advanced Clinical Therapeutics, LLC
    Tucson, Arizona 85712, United States
  • Arkansas Primary Care Clinic, PA
    Little Rock, Arkansas 72204, United States
  • Care Access Research LLC
    San Pablo, California 94806, United States
  • Care Access Research, San Pablo
    San Pablo, California 94806, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06066, United States
  • Gastro Florida
    Clearwater, Florida 33756, United States
  • Florida Research Network, LLC
    Gainesville, Florida 32605, United States
  • Wellness Clinical Research, LLC
    Hialeah, Florida 33016, United States
  • Center for Advanced Gastro
    Maitland, Florida 32751, United States
  • Center for Interventional Endo
    Orlando, Florida 32803, United States
  • BRCR Medical Center, Inc.
    Pembroke Pines, Florida 33028, United States
  • Gastro Florida
    Tampa, Florida 33626, United States
  • Atlanta Gastroenterology Specialists, PC
    Atlanta, Georgia 30308, United States
  • Atlanta Center for Gastroenterology
    Decatur, Georgia 30033, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Aquiant Research
    New Albany, Indiana 47150, United States
  • Iowa Digestive disease center
    Clive, Iowa 50325, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66604, United States
  • Gastroenterology Associates LLC
    Baton Rouge, Louisiana 70809, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • 4940 Eastern Ave A building
    Baltimore, Maryland 21224, United States
  • Gastro Center of Maryland
    Columbia, Maryland 20721, United States
  • Woodholme Gastroenterology Associates
    Glen Burnie, Maryland 21061, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Charlotte Gastroenterology and Hepatology
    Charlotte, North Carolina 28207, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Gastroenterology Associates PA
    Greenville, South Carolina 29615, United States
  • Midwest Medical Care
    Sioux Falls, South Dakota 57105, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37212, United States
  • Texas Digestive Disease Consultants - Dallas
    Dallas, Texas 75231, United States
  • Ygenics
    Decatur, Texas 76234, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Texas Digestive Disease Consultants
    Keller, Texas 76248, United States
  • DHAT Research Institute
    Richardson, Texas 75082, United States
  • Texas Digestive Disease Consultants - Southlake
    Southlake, Texas 76092, United States
  • BaylorScott&White Research Institute
    Temple, Texas 76508, United States
  • GI Liver Research LLC
    Webster, Texas 77598, United States
  • Gastroenterology Associates of Northern Virginia, Ltd.
    Fairfax, Virginia 22031, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53266, United States
  • PerCuro Clinical Research Ltd.
    Victoria, British Colombia V8V 3M9, Canada
  • LHSC - University Hospital
    London, Ontario N6A 5A5, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Taunton Surgical Centre
    Oshawa, Ontario L1H 7K4, Canada
  • Toronto Digestive Disease Associates, Inc.
    Vaughan, Ontario L4L4Y7, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Oct 2020, 42 months.

Results were first posted in Nov 2021, 1 year after primary completion.

Of 63 phase 4 interventional studies under Colitis, Ulcerative, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 63. This study's 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Mar 29, 2017
Primary completionActual
Oct 16, 2020
CompletionActual
Oct 16, 2020
Results first posted
Nov 11, 2021
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03029143
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Mar 29, 2017
Primary completion
Oct 16, 2020
Completion
Oct 16, 2020
Results posted
Nov 11, 2021
Last update
Jul 28, 2023

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion